2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 21:44, 10 December 2023
, 10 December 2023→Clinical Trials
| Line 220: | Line 220: | ||
| | | | ||
*10 healthy men | *10 healthy men | ||
*40-60 | *age 40-60 | ||
| | | | ||
*admission was safe and well-tolerated | *admission was safe and well-tolerated | ||
| Line 231: | Line 231: | ||
*25 postmenopausal women with prediabetes | *25 postmenopausal women with prediabetes | ||
*overweight or obese (BMI 25.3 - 39.1) | *overweight or obese (BMI 25.3 - 39.1) | ||
*56 - 66 | *age 56-66 | ||
| | | | ||
*increase in skeletal muscle insulin signaling, insulin sensitivity, and muscle remodeling | *increase in skeletal muscle insulin signaling, insulin sensitivity, and muscle remodeling | ||
| Line 244: | Line 244: | ||
| | | | ||
*48 young and middle-aged recreationally trained runners | *48 young and middle-aged recreationally trained runners | ||
*35 | *age 35 average | ||
| | | | ||
*The combination of NMN supplementation and exercise further improves ventilatory threshold even among healthy young and middle-aged people. | *The combination of NMN supplementation and exercise further improves ventilatory threshold even among healthy young and middle-aged people. | ||
| Line 258: | Line 258: | ||
| | | | ||
* 8 healthy men | * 8 healthy men | ||
* age | * age 45–60 | ||
|* | |* | ||
| Line 270: | Line 270: | ||
| | | | ||
*31 healthy adult men and women | *31 healthy adult men and women | ||
*20–65 | *age 20–65 | ||
| | | | ||
*Oral administration of 1250 mg of NMN, when administered once daily for up to 4 weeks, was safe and well-tolerated in healthy adult men and women. | *Oral administration of 1250 mg of NMN, when administered once daily for up to 4 weeks, was safe and well-tolerated in healthy adult men and women. | ||
| Line 285: | Line 285: | ||
| | | | ||
*108 older adults | *108 older adults | ||
* | *age ≥ 65 | ||
| | | | ||
*NMN intake in the afternoon is more effective in improving lower limb function and reducing drowsiness in older adults. | *NMN intake in the afternoon is more effective in improving lower limb function and reducing drowsiness in older adults. | ||
| Line 296: | Line 296: | ||
| | | | ||
* 20 healthy male | * 20 healthy male | ||
* | * age ≥ 65 | ||
* BMI 22–28 | * BMI 22–28 | ||
* nonsmokers | * nonsmokers | ||
| Line 324: | Line 324: | ||
| | | | ||
*healthy males and females | *healthy males and females | ||
*40-65 | *age 40-65 | ||
*BMI between 18.5 and 35 | *BMI between 18.5 and 35 | ||
| | | | ||
| Line 339: | Line 339: | ||
| | | | ||
*32 overweight or obese adults | *32 overweight or obese adults | ||
*55-80 | *age 55-80 | ||
| | | | ||
*MIB-626 was well tolerated | *MIB-626 was well tolerated | ||
| Line 354: | Line 354: | ||
| | | | ||
*30 overweight or obese adults | *30 overweight or obese adults | ||
* | *age ≥ 45 | ||
| | | | ||
*MIB-626 treatment increased circulating NAD and metabolites | *MIB-626 treatment increased circulating NAD and metabolites | ||